Elizabeth M. Swisher

Also affiliated with Fred Hutch Cancer Center, University of Washington Applied Physics Laboratory, Woman's Cancer Foundation

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 1%percentile

14.8Author DataRank

Indexed papers

7in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 7 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

Cell(2018)10.1016/j.cell.2018.02.052

Top 2%

8.1DataRank

Top 2%3980 citations

Katherine A. Hoadley, Laila M. Poisson, Alexander J. Lazar, Andrew D. Cherniack, Albert J. Kovatich +866 more

Papers

Driven by 69 papers — median percentile 35. Top paper: “An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics”.

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

Cell(2018)10.1016/j.cell.2018.02.052

Top 2%

8.1DataRank

Top 2%3980 citations

Katherine A. Hoadley, Laila M. Poisson, Alexander J. Lazar, Andrew D. Cherniack, Albert J. Kovatich +866 more

Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics

Cell(2018)10.1016/j.cell.2018.03.033

Top 3%

6.4DataRank

Top 3%447 citations

Matthew H. Bailey, Hoifung Poon, Vesteinn Thorsson, Antonio Colaprico, Andreas Bender +883 more

Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas

Cell Reports(2018)10.1016/j.celrep.2018.03.046

N/A

5.5DataRank · unranked

186 citations

Francisco Sanchez-Vega, Konnor C. La, Joshua Armenia, Walid K. Chatila, Augustin Luna +869 more

Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial

Journal of Clinical Oncology(2022)10.1200/jco.21.02011

N/A

2.6DataRank · unranked

88 citations

Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher +16 more

Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma

Cancer Research(2021)10.1158/0008-5472.can-21-0774

N/A

2.1DataRank · unranked

90 citations

Olga Kondrashova, Rachel M. Hurley, Cordelia D. McGehee, Cassandra J. Vandenberg, Gwo‐Yaw Ho +25 more

Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Oncology(2023)10.1016/s1470-2045(22)00739-2

N/A

2.0DataRank · unranked

102 citations

Priyanka Sharma, William E. Barlow, Julie R. Gralow, Shannon L. Puhalla, Carey K. Anders +16 more

Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3045

N/A

1.5DataRank · unranked

64 citations

Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann, Lewis C. Cantley +10 more

Oncogenic Signaling Pathways in The Cancer Genome Atlas

Cell(2018)10.1016/j.cell.2018.03.035

N/A

1.2DataRank · unranked

3322 citations

Marco Mina, Joshua Armenia, Walid K. Chatila, Augustin Luna, Konnor C. La +891 more

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.05.045

N/A

0.920DataRank · unranked

18 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean +21 more

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer

Science Translational Medicine(2023)10.1126/scitranslmed.add7872

N/A

0.790DataRank · unranked

25 citations

Tzu‐Ting Huang, Jayakumar R. Nair, Daniel An, Grant Zurcher, Erika J. Lampert +12 more

Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING

Cell Reports(2021)10.1016/j.celrep.2021.109412

N/A

0.742DataRank · unranked

140 citations

David Barras, Marco Mina, Eleonora Ghisoni, Matteo Morotti, Evripidis Lanitis +30 more

A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.6003

N/A

0.606DataRank · unranked

56 citations

Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher +15 more

Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1789

N/A

0.601DataRank · unranked

54 citations

Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian +11 more

Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.1001

N/A

0.587DataRank · unranked

49 citations

Eve T. Rodler, William E. Barlow, Julie R. Gralow, Shannon Leigh Huggins-Puhalla, Carey K. Anders +15 more

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial

Nature Communications(2024)10.1038/s41467-024-47215-6

N/A

0.571DataRank · unranked

44 citations

Tzu‐Ting Huang, Jayakumar R. Nair, Grant Zurcher, Ann McCoy, Darryl Nousome +14 more

Comparative genomics of high grade neuroendocrine carcinoma of the cervix

PLoS ONE(2020)10.1371/journal.pone.0234505

N/A

0.568DataRank · unranked

43 citations

Robert J. Cardnell, Junya Fujimoto, Won-Chul Lee, Jianjun Zhang, Lauren A. Byers +6 more

A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer

Cancer Chemotherapy and Pharmacology(2022)10.1007/s00280-022-04430-6

N/A

0.560DataRank · unranked

10 citations

Shannon Puhalla, Shalu Pahuja, Fei Ding, Yan Lin, Leonard J. Appleman +30 more

Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.02.006

N/A

0.510DataRank · unranked

29 citations

Elizabeth M. Swisher, Rochelle L. Garcia, Kathryn P. Pennington, Kathy Agnew, Mark Kilgore +2 more

Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing

npj Precision Oncology(2023)10.1038/s41698-023-00379-8

N/A

0.500DataRank · unranked

27 citations

Payel Chatterjee, Rachele Rosati, Lauren R. Appleyard, Grace J. Durenberger, Robert L. Diaz +14 more

Strategies to Assess Risk for Hereditary Cancer in Primary Care Clinics

JAMA Network Open(2025)10.1001/jamanetworkopen.2025.0185

N/A

0.427DataRank · unranked

7 citations

Heather M. Harris, Sarah Knerr, Tesla Theoryn, Barbara M. Norquist, Jeannine M. Brant +11 more

Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9065

N/A

0.360DataRank · unranked

10 citations

Navid Hafez, Hatem Soliman, Siqing Fu, Shumei Kato, Primo N. Lara +12 more

Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1 germline mutations

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.07.690

N/A

0.358DataRank · unranked

5 citations

Emma Hazard, Elena Latorre‐Esteves, Brendan Kohrn, Talayeh Ghezelayagh, Jeanne Uy Fredrickson +9 more

State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report

JCO Precision Oncology(2022)10.1200/po.22.00355

N/A

0.330DataRank · unranked

8 citations

Katherine C. Fuh, Rebecca C. Arend, Gottfried E. Konecny, Panagiotis A. Konstantinopoulos, Kunle Odunsi +4 more

Primary care provider practices, attitudes, and confidence with hereditary cancer risk assessment and testing: A mixed methods study

Genetics in Medicine(2024)10.1016/j.gim.2024.101307

N/A

0.312DataRank · unranked

7 citations

Tesla Theoryn, Emerson J. Dusic, Faith Beers, Sarah Knerr, Barbara M. Norquist +5 more

Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.1077

N/A

0.312DataRank · unranked

7 citations

Hatem Soliman, Siqing Fu, Karen A. Gelmon, Albiruni Ryan Abdul Razak, Pamela N. Münster +11 more

Impact of Global Enrollment on Race, Ethnicity, and Age Representation in Pivotal Gynecologic Cancer Trials Leading to US Food and Drug Administration Drug Approvals

JCO Global Oncology(2025)10.1200/go-24-00636

Top 65%

0.208DataRank

Top 65%3 citations

Kristen R. Ibanez, Courtney Bowen, Duncan Donohue, Ann Oluloro, Elizabeth M. Swisher +2 more

Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitors

Molecular Cancer(2024)10.1186/s12943-024-02125-5

N/A

0.208DataRank · unranked

3 citations

Cristina Correia, Kevin L. Peterson, Xianon Hou, Paula A. Schneider, Annabella R. Strathman +16 more

TP53 somatic evolution in the normal endometrium of Black and White individuals

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.04.002

N/A

0.165DataRank · unranked

2 citations

Elizabeth U. Parker, Brendan Kohrn, Mindy Pike, Coohleen Coombes, Elena Latorre‐Esteves +7 more

Neoplastic and blood-based biomarkers of response in patients with advanced endometrial cancer: Results from NRG GY012.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5525

N/A

0.104DataRank · unranked

1 citations

Andrew B. Nixon, Danielle Enserro, David Bender, B.J. Rimel, Matthew A. Powell +12 more

Homologous recombination deficiency (HRD) by BROCA-HR and survival outcomes after surgery for patients (pts) with pancreatic adenocarcinoma (PC): A single institution experience.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.732

N/A

0.104DataRank · unranked

1 citations

David B. Zhen, Marc R. Radke, Kelsey K. Baker, Andrew L. Coveler, Kit Man Wong +5 more

Reviewer #1 (Public Review): Identification of fallopian tube microbiota and its association with ovarian cancer: a prospective study of intraoperative swab collections from 187 patients

(2023)10.7554/elife.89830.1.sa2

N/A

0DataRank · unranked

0 citations

Congzhou Liu, Sean Proll, Enna Mannhardt, Shuying Liang, Sujatha Srinivasan +3 more

The role of aberrant DNA methylation in cancer initiation and clinical impacts

Therapeutic Advances in Medical Oncology(2024)10.1177/17588359231220511

N/A

0DataRank · unranked

94 citations

Ksenija Nesic, Olga Kondrashova, Alexander Dobrovic, Elizabeth M. Swisher, Clare L. Scott +2 more

Identification of fallopian tube microbiota and its association with ovarian cancer

eLife(2024)10.7554/elife.89830.3

N/A

0DataRank · unranked

7 citations

Congzhou Liu, Sean Proll, Enna Manhardt, Shuying Liang, Sujatha Srinivasan +3 more

Identification of fallopian tube microbiota and its association with ovarian cancer: a prospective study of intraoperative swab collections from 187 patients

eLife(2024)10.7554/elife.89830.2

N/A

0DataRank · unranked

1 citations

Congzhou Liu, Sean Proll, Enna Mannhardt, Shuying Liang, Sujatha Srinivasan +3 more

Author Response: Identification of fallopian tube microbiota and its association with ovarian cancer: a prospective study of intraoperative swab collections from 187 patients

(2024)10.7554/elife.89830.2.sa3

N/A

0DataRank · unranked

0 citations

Congzhou Liu, Sean Proll, Enna Mannhardt, Shuying Liang, Sujatha Srinivasan +3 more

DNA repair and the contribution to chemotherapy resistance

Genome Medicine(2025)10.1186/s13073-025-01488-8

N/A

0DataRank · unranked

26 citations

Phoebe Parker, Elizabeth M. Swisher, John J. Krais, Ksenija Nešić

Comprehensive RAD51C ovarian cancer variant analysis uncouples homologous recombination and replicative functions

Nature Communications(2025)10.1038/s41467-025-61283-2

N/A

0DataRank · unranked

7 citations

Yashpal Rawal, Anna L Palovcak-Lightbourn, Gayatri S. Ganesan, Phoebe S. Parker, Reagan A Russell +15 more

Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity

Experimental Hematology and Oncology(2025)10.1186/s40164-025-00681-0

N/A

0DataRank · unranked

1 citations

Jill M. Wagner, Arun Kanakkanthara, Annapoorna Venkatachalam, Aaron M Deisinger, Cristina Correia +18 more

Codon specific readthrough as a mechanism of BRCA2 restoration in acquired PARP inhibitor and chemotherapy resistance

Nucleic Acids Research(2025)10.1093/nar/gkaf990

N/A

0DataRank · unranked

1 citations

X. Wei Meng, Xinyan Wu, Cristina Correia, Annapoorna Venkatachalam, Karen S. Flatten +15 more

Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer

Cancer Cell(2025)10.1016/j.ccell.2025.07.005

N/A

0DataRank · unranked

24 citations

Fabrizio Benedetti, Aspram Minasyan, Mathieu Desbuisson, Paula Cunnea, Alizée J Grimm +37 more

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-0056

N/A

0DataRank · unranked

224 citations

Alexandra S. Zimmer, Michelle R. Padget, Ashley Cimino‐Mathews, Jayakumar R. Nair, Yingmiao Liu +13 more

Design of a study to implement population-based risk assessment for hereditary cancer genetic testing in primary care

Contemporary Clinical Trials(2020)10.1016/j.cct.2020.106257

N/A

0DataRank · unranked

13 citations

Catharine Wang, Allison Cole, Barbara M. Norquist, Sarah Knerr, Beth Devine +6 more

Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.12.007

N/A

0DataRank · unranked

40 citations

Kathryn P. Pennington, Barbara M. Norquist, Nithisha Khasnavis, Marc R. Radke, Mark Kilgore +7 more

BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer

EBioMedicine(2020)10.1016/j.ebiom.2020.102988

N/A

0DataRank · unranked

38 citations

Reid Shaw, Franz X. Schaub, Isabella N. Stork, Kay E. Gurley, Caroline Bridgwater +11 more

Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.12.10.419176

N/A

0DataRank · unranked

2 citations

Olga Kondrashova, Rachel M. Hurley, Cordelia D. McGehee, Cassandra J. Vandenberg, Gwo‐Yaw Ho +26 more

Characterization of a RAD51C -Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance Development

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.12.25.419978

N/A

0DataRank · unranked

2 citations

Cordelia D. McGehee, Ksenija Nesic, Cristina Correia, Taylor M. Weiskittel, Rebecca L. Kelly +25 more

Characterization of a RAD51C -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance

NAR Cancer(2021)10.1093/narcan/zcab028

N/A

0DataRank · unranked

37 citations

Cordelia D. McGehee, Ksenija Nesic, Cristina Correia, Taylor M. Weiskittel, Rebecca L. Kelly +28 more

Progesterone Receptors Promote Quiescence and Ovarian Cancer Cell Phenotypes via DREAM in p53-Mutant Fallopian Tube Models

The Journal of Clinical Endocrinology & Metabolism(2021)10.1210/clinem/dgab195

N/A

0DataRank · unranked

22 citations

Megan Seibel, Caroline H. Diep, Angela Spartz, Carlos Perez Kerkvliet, Hari Singhal +8 more

Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3

International Journal of Gynecological Cancer(2021)10.1136/ijgc-2020-002240

N/A

0DataRank · unranked

15 citations

Domenica Lorusso, Amit M. Oza, Carol Aghajanian, Ana Oaknin, Andrew Dean +18 more

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety

Cancer Medicine(2021)10.1002/cam4.4260

N/A

0DataRank · unranked

6 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Andrew Dean, Nicoletta Colombo +19 more

Analysis of homologous recombination DNA repair gene mutation status in patients with metastatic small cell lung cancer treated with cediranib and olaparib on NCI 9881 study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.8563

N/A

0DataRank · unranked

0 citations

Marc R. Radke, Navid Hafez, Hatem Soliman, Siqing Fu, Shumei Kato +11 more

Specific BRCA and immune configurations determine optimal response to platinum-based chemotherapy in triple negative breast and ovarian carcinomas

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.08.19.456799

N/A

0DataRank · unranked

0 citations

Kalyan Banda, Pooja Kumar, Robert F. Straub, Lacey E. Dobrolecki, Isabel V. Rodriguez +10 more

Barriers, interventions, and recommendations: Improving the genetic testing landscape

Frontiers in Digital Health(2022)10.3389/fdgth.2022.961128

N/A

0DataRank · unranked

74 citations

Tesla Theoryn, Catharine Wang, Elizabeth M. Swisher, Deborah J. Bowen, EDGE Study Team +1 more

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.08.021

N/A

0DataRank · unranked

57 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean +17 more

Socioeconomic Status and Interest in Genetic Testing in a US-Based Sample

Healthcare(2022)10.3390/healthcare10050880

N/A

0DataRank · unranked

21 citations

Deborah J. Bowen, Robin L. Bennett, Kevin C. Cain, Tesla Theoryn, Mariebeth Velasquez +5 more

Uterine Lavage Identifies Cancer Mutations and Increased TP53 Somatic Mutation Burden in Individuals with Ovarian Cancer

Cancer Research Communications(2022)10.1158/2767-9764.crc-22-0314

N/A

0DataRank · unranked

11 citations

Brendan Kohrn, Jeanne Fredrickson, Enna Manhardt, Marc R. Radke, Ronit Katz +13 more

SWOG S2012: Randomized phase II/III trial of first line platinum/etoposide (P/E) with or without atezolizumab (NSC#783608) in patients (pts) with poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4179

N/A

0DataRank · unranked

5 citations

Edward Mayerson, E. Gabriela Chiorean, Earle F. Burgess, Elizabeth M. Swisher, Carl M. Gay +9 more

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA-mutant ovarian cancer

medRxiv(2022)10.1101/2022.12.02.22283037

N/A

0DataRank · unranked

2 citations

Tzu‐Ting Huang, Jayakumar R. Nair, Daniel An, Grant Zurcher, Erika J. Lampert +12 more

R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication Conflicts

Cancer Research(2023)10.1158/0008-5472.can-23-3239

N/A

0DataRank · unranked

27 citations

Sayantani Sinha, Maxwell Bannister, Axia Song, Erica Arriaga-Gomez, Alexander J. McKeeken +25 more

Identification of fallopian tube microbiota and its association with ovarian cancer

eLife(2023)10.7554/elife.89830

N/A

0DataRank · unranked

8 citations

Congzhou Liu, Sean Proll, Enna Manhardt, Shuying Liang, Sujatha Srinivasan +3 more

Diagnosis of Ovarian Carcinoma Homologous Recombination DNA Repair Deficiency From Targeted Gene Capture Oncology Assays

JCO Precision Oncology(2023)10.1200/po.22.00720

N/A

0DataRank · unranked

6 citations

Nithisha Khasnavis, Marc R. Radke, Kalyan Banda, Helen Davies, Christopher C. Pennil +10 more

What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women

Gynecologic Oncology(2023)10.1016/j.ygyno.2023.03.002

N/A

0DataRank · unranked

4 citations

Sarah M. Temkin, Jonathan Jackson, Elizabeth M. Swisher, Liz Sage, Kemi M. Doll +1 more

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance

medRxiv(2023)10.1101/2023.03.20.23287465

N/A

0DataRank · unranked

9 citations

John J. Krais, Cassandra J. Vandenberg, Yifan Wang, Pooja Patel, Kathy Q. Cai +30 more

Identification of fallopian tube microbiota and its association with ovarian cancer: a prospective study of intraoperative swab collections from 187 patients

medRxiv(2023)10.1101/2023.06.28.23291999

N/A

0DataRank · unranked

1 citations

Congzhou Liu, Sean Proll, Enna Mannhardt, Shuying Liang, Sujatha Srinivasan +3 more

Data from Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

(2023)10.1158/1078-0432.c.6532290.v1

Top 100%

0DataRank

Top 100%0 citations

Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann, Lewis C. Cantley +10 more

Data from Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

(2023)10.1158/1078-0432.c.6532290

Top 100%

0DataRank

Top 100%0 citations

Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann, Lewis C. Cantley +10 more

Data from Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma

(2023)10.1158/0008-5472.c.6513498.v1

N/A

0DataRank · unranked

0 citations

Olga Kondrashova, Rachel M. Hurley, Cordelia D. McGehee, Cassandra J. Vandenberg, Gwo‐Yaw Ho +25 more

Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

(2023)10.1158/1078-0432.c.6531176

N/A

0DataRank · unranked

0 citations

Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian +11 more

Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

(2023)10.1158/1078-0432.c.6531176.v1

N/A

0DataRank · unranked

0 citations

Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian +11 more

Elizabeth M. Swisher

Indexed papers

Top data-sharing exemplar

Papers